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aspartate (NMDA) are involved in embryonic brain develop-
ment but their activity may be modulated by the kynurenine
pathway of tryptophan metabolism which includes an ago-
nist (quinolinic acid) and an antagonist (kynurenic acid) at
these receptors. Our previous work has shown that prenatal
inhibition of the pathway produces abnormalities of brain
development. In the present study kynurenine and probene-
cid (both 100 mg/kg, doses known to increase kynurenic
acid levels in the brain) were administered to female Wistar
rats on embryonic days E14, E16 and E18 of gestation and
the litter was allowed to develop to post-natal day P60. Wes-
tern blotting revealed no changes in hippocampal expres-
sion of several proteins previously found to be altered by
inhibition of the kynurenine pathway including the NMDA
receptor subunits GluN1, GluN2A and GluN2B, as well as
doublecortin, Proliferating Cell Nuclear Antigen (PCNA),
sonic hedgehog and unco-ordinated (unc)-5H1 and 5H3.
Mice lacking the enzyme kynurenine-3-monoxygenase
(KMO) also showed no changes in hippocampal expression
of several of these proteins or the 70-kDa and 100-kDa vari-
ants of Disrupted in Schizophrenia-1 (DISC1). Electrical
excitability of pyramidal neurons in the CA1 region of
hippocampal slices was unchanged, as was paired-pulse
facilitation and inhibition. Long-term potentiation was
decreased in the kynurenine-treated rats and in the KMO
(/) mice, but galantamine reversed this eﬀect in the pres-
ence of nicotinic receptor antagonists, consistent with evi-
dence that it can potentiate glutamate at NMDA receptors.
It is concluded that interference with the kynurenine path-
way in utero can have lasting eﬀects on brain function of
the oﬀspring, implying that the kynurenine pathway is
involved in the regulation of early brain development.http://dx.doi.org/10.1016/j.neuroscience.2015.09.022
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INTRODUCTION
The activation of N-methyl-D-aspartate (NMDA) receptors
has been implicated in many aspects of brain
development in the early embryo. Neural precursor
migration, neurite generation or guidance and the
formation of synaptic connections are all inﬂuenced by
these receptors (Simon et al., 1992; Ernst et al., 1998;
Rajan and Cline, 1998; Heng et al., 1999; Cuppini et al.,
1999; Udin and Grant, 1999; Colonnese et al., 2005;
Alvarez et al., 2007; Ultanir et al., 2007). These and other
aspects of neuronal and synaptic development ultimately
determine synaptic function and plasticity in the mature,
postnatal, oﬀspring (Iwasato et al., 2000; Myers et al.,
2000; Ramoa et al., 2001; Fagiolini et al., 2003). Their
importance is reﬂected in the loss of neurons and
synapses following treatment of animals with NMDA
receptor blocking agents (Ikonomidou et al., 1999;
Dikranian et al., 2001; Harris et al., 2003; Vincent et al.,
2004), which can result in signiﬁcant central abnormalities
of structure and behavior comparable with those seen in
schizophrenia and other CNS disorders (Cochran et al.,
2003; Harris et al., 2003; du Bois and Huang, 2007;
Stone and Darlington, 2013).
Despite this fundamental role for NMDA receptors,
little is known of the factors that might regulate their
sensitivity during early brain formation. One potential
source of regulation is the kynurenine pathway of
tryptophan metabolism, which includes an agonist
(quinolinic acid) and an antagonist (kynurenic acid) at
NMDA receptors. We have reported that prenatal
inhibition of this pathway does lead to structural and
functional changes in the adult rat hippocampus.
Inhibition of kynurenine-3-monoxygenase (KMO) by 3,4-
dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]-benzene-sulfo
namide (Ro61-8048) or related compounds (Ceresoli-
Borroni et al., 2007) in late gestation produced changes
in kynurenic acid levels in the brain. Changes in protein
expression in the embryo brain can be seen within 5 h
(Forrest et al., 2013a), with some of those changes, and/licenses/by/4.0/).
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structure, persisting until postnatal day 21 (P21) or adult-
hood at P60 (Forrest et al., 2013a,b; Khalil et al., 2014;
Pisar et al., 2014).
Since pharmacological enzyme inhibitors may have
unrecognized eﬀects at oﬀ-target enzymes, we set out
to compare the eﬀects of other methods of elevating
kynurenic acid concentrations in the CNS on the
hypothesis that these should generate similar results
dependent on kynurenate levels. Firstly, kynurenine has
been injected directly into rats prenatally in conjunction
with the acidic transport inhibitor probenecid.
Kynurenine can readily cross the blood–brain barrier
and the placental barrier, where it is then converted to
kynurenic acid by kynurenine aminotransferases (KAT),
permitting kynurenic acid levels to be increased in the
embryonic or adult brain without relying on the potency
or selectivity of an enzyme inhibitor. The presence of
probenecid reduces the eﬄux of kynurenic acid from
tissues as its concentration rises, eﬀectively trapping
kynurenate within regions dependent on acidic ion
transporters for excretion, such as the brain. The
combination is well documented to increase kynurenate
levels in brain by 10–100-fold (Vecsei et al., 1992; Miller
et al., 1992; Shepard et al., 2003; Alexander et al.,
2013; Chess et al., 2007; Pocivavsek et al., 2012,
2014). Since the conversion of injected kynurenine to
kynurenic acid has been reported to peak after approxi-
mately 3 days (Vecsei et al., 1992) and to have returned
to control levels by 6 days (Trecartin and Bucci, 2011),
we administered three injections of kynurenine, 48 h
apart, in late gestation at embryonic days E14, E16 and
E18, a time frame which should produce continually ele-
vated levels of kynurenate throughout the ﬁnal third of
gestation. This sequence is the same as that used in
our previous work, allowing for a direct comparison
between the various models (Forrest et al., 2013a).
Secondly, we have employed mice in which the
enzyme KMO has been deleted (Giorgini et al., 2013).
The enzyme normally oxidises kynurenine to
3-hydroxykynurenine and thus to 3-hydroxy-anthranilic
acid and quinolinic acid. The absence, or inhibition, of
the enzyme suppresses these reactions but causes an
accumulation of kynurenine which is transaminated to
kynurenic acid. A deﬁciency of KMO should, therefore,
have a range of inhibitory and neuroprotective actions
that are comparable with those described using KMO
inhibitors such as nicotinylalanine or Ro61-8048 (Ro¨ver
et al., 1997; Forrest et al., 2013a,b; Khalil et al., 2014).
The mice have been fully characterized by Giorgini et al.
(2013) who recorded kynurenic acid concentration
increases of 69-, 159- and 12-fold greater than Wild-Type
animals in the liver, blood and brains of these mice, which
should be maintained throughout the life of the animals.
In view of the absence of diﬀerences in NMDA
receptor protein expression and neural excitability in
control animals and those with raised kynurenate levels,
we considered the possibility that some of the eﬀects of
the increased kynurenate could be mediated through
actions on a7-nicotinic cholinoceptors. It has been
claimed that some eﬀects of kynurenic acid may be dueto a blockade of nicotinic receptors (Hilmas et al., 2001;
Alkondon et al., 2003, 2011), although several groups
have failed to conﬁrm this (Arnaiz-Cot et al., 2008; Mok
et al., 2009; Dobelis et al., 2012), have only seen eﬀects
at high concentrations in young animals (Stone, 2007) or
have obtained results inconsistent with it (Tuboly et al.,
2015). Indeed, much of the evidence for an action of
kynurenate on nicotinic receptors revolves around the
reversal of its eﬀects by galantamine on the basis that it
is an allosteric enhancer at nicotinic cholinoceptors. How-
ever, galantamine can also potentiate the activation of
NMDA receptors (Moriguchi et al., 2004) and we have
now examined the eﬀect of galantamine directly on LTP
with and without the pre-treatment regime of kynurenine
and probenecid but in the presence of nicotinic antago-
nists in an eﬀort to help resolve these questions.
There are important clinical implications for this work
since activity along the kynurenine pathway is strongly
induced and enhanced by immune system activity and
the presence of pro-inﬂammatory cytokines, raising the
strong possibility that stress (via glucocorticoids and
tryptophan-2,3-dioxygenase, TDO) or infection (via
indolamine-2,3-dioxygenase, IDO) could have not only
acute and transient eﬀects on cerebral function but, if
experienced during gestation could signiﬁcantly interfere
with brain development. Other links with the immune
system may also be relevant, since several kynurenine
metabolites can modulate immune function (Nguyen
et al., 2010; Stone et al., 2013) to a degree which may
contribute to the results reported here.
EXPERIMENTAL PROCEDURES
This study was carried out according to the regulations of
the Animals (Scientiﬁc Procedures) act 1986 of the UK,
administered and monitored by the Home Oﬃce. Male
and female Wistar rats were housed together for mating
and inspected daily for the occurrence of a vaginal plug.
All animals were provided with free access to food and
water for at least two weeks before use.
In order to maximize the period of development during
which the activity of the kynurenine pathway is aﬀected by
kynurenine administration, we administered kynurenine
(100 mg/kg i.p.) with probenecid (100 mg/kg i.p.) to the
pregnant dam at days E14, E16 and E18 of gestation.
The doses were selected on the basis of previous
studies which have found that these doses can raise
tissue levels of kynurenic acid several-fold while
producing little or no sign of toxicity (Miller et al., 1992;
Nozaki and Beal, 1992; Vecsei et al., 1992; Alexander
et al., 2013; Chess et al., 2007; Pocivavsek et al., 2012,
2014). The timing of injections was predicated on the
intention to restrict elevated kynurenate levels to embry-
onic brain development, as inﬂuenced by maternal fac-
tors, rather than post-natal factors in the neonate itself.
The objective in selecting this protocol was to reproduce
the extent and time course of raised kynurenate levels
for comparison with our previous studies (Forrest et al.,
2013a).
Groups of control pregnant animals were injected with
vehicle (0.9% NaCl in water). Gestation was then allowed
to proceed normally, with male neonates being separated
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when they were euthanized and the brains removed for
examination of the neocortex and hippocampus.
Twelve male KMO(/) mice and 12 Wild-Type
controls between 30 and 40 weeks of age were bred
in-house from breeding animals supplied by Prof. F.
Giorgini (University of Leicester, UK) and Prof. R.
Schwarcz (University of Maryland, USA). They were
housed in barrier ﬁlter top cages in groups of six
animals with knockout and Wild-Type animals housed
separately.
Electrophysiology
Electrophysiological studies were performed on male
kynurenine-treated rats (as above) which were allowed
to wean and grow under normal conditions to 60 days of
age (P60). The KMO-deﬁcient mice were used for
electrophysiological study when adult at approximately
30 weeks of age. Animals were killed by administration
of an overdose of urethane (2.5 g/kg delivered as an i.p.
injection of a 25% solution in water) followed by cervical
dislocation. The brain was removed into ice-cold artiﬁcial
cerebrospinal ﬂuid (aCSF) of composition: (in mM) NaCl
115; KH2PO4 2.2; KCl 2; MgSO4 1.2; NaHCO3 25;
CaCl2 2.5; glucose 10, gassed with 5%CO2 in oxygen.
The hippocampi were rapidly removed and chopped into
450-lm transverse slices using a McIlwain tissue
chopper. The slices were pre-incubated at room
temperature for at least 1 h in a water-saturated
atmosphere of 5%CO2 in O2 before individual slices
were transferred to a 1 ml capacity superfusion chamber
for recording.
Slices were superfused at 28–30 C using aCSF at a
ﬂow rate of 3–4 ml/min. A concentric bipolar electrode was
used for stimulation of the Schaﬀer collateral and
commissural ﬁbers in stratum radiatum, using stimuli
delivered at 0.1 Hz with a pulse width of 300 ls, at a
stimulus strength adjusted to evoke a response amplitude
of approximately 70% of maximum to allow increases or
decreases in size to be detected. Extracellular recordings
were made via glass microelectrodes containing 1 M NaCl
(tip diameter approximately 2 lm, DC resistances 2–5 MX)
with the tip positioned under microscopic visualization in
the stratum radiatum of the CA1 region to evoke ﬁeld
excitatory postsynaptic potentials (fEPSPs). Potentials
were ampliﬁed, digitized, and stored in computer via a
CED (Cambridge Electronic Design, Cambridge, UK))
micro1401 interface. The fEPSPs were routinely quantiﬁed
by measurement of the early positive slope of the
potential, using Signal software (CED, Cambridge, UK).
The axonal volley was monitored wherever it was possible
to distinguish it clearly from the fEPSP in order to ensure
that no change occurred during the experiments.
Once placed into the recording chamber, the
recording of fEPSPs was allowed to stabilize and a
minimum period of 10 min obtained at a stable baseline.
Paired-pulse interactions were assessed in slices not
used for the examination of LTP, using pairs of stimuli
S1 and S2 with inter-stimulus intervals of 10–100 ms. In
the case of fEPSPs the 10-ms interval resulted in a
substantial overlap between successive potentials andan electronic subtraction was performed in which a
single evoked potential at time S1 was subtracted from
a subsequent paired-pulse response to reveal the true
magnitude of the response to S2 (Forrest et al., 2013a,b).
Long-term potentiation (LTP) was induced by theta-
burst stimulation (ﬁve bursts per second, for 2 s, of four
stimuli delivered at 100 Hz; Larson et al., 1986). The
degree of LTP was quantiﬁed by measuring the amplitude
of the evoked fEPSPs once a post-stimulation plateau
had been obtained and comparing with the size of the
potentials before theta stimulation.
Immunoblotting
Homogenates were prepared in RIPA buﬀer (50 mM Tris,
150 mM NaCl, 0.1% SDS, 0.5% Triton X-100, 1%
IGEPAL, and a Roche complete protease inhibitor
tablet) and centrifuged at 18,000g for 5 min at 4 C.
Supernatants were collected for protein concentration
determination using the Bio-Rad protein assay (Bio-Rad,
Hemel Hempstead, UK). Samples were then normalized
to 10 lg and prepared as follows: 65% protein sample,
25% sample buﬀer and 10% reducing agent (Life
Technologies, Paisley, UK) and heated at 70 C for
10 min. The protein samples were loaded onto NuPAGE
Novex 4–12% Bis–Tris (1.0 mm) 15 or 17 lane gels (Life
Technologies, Paisley, UK) and run at 175 V for 70 min
to separate proteins according to their molecular weight.
SeeBlue pre-stained standard (10 lL) (Life
Technologies, Paisley, UK) was included on each gel as
a molecular weight marker. The separated proteins
were then blotted onto Invitrolon polyvinylidene
diﬂuoride) membranes (Life Technologies, Paisley, UK)
at 35 V for 75 min. After rinsing well with distilled water,
membranes were blocked for 1 h in 5% non-fat dried
milk solution in Tris-buﬀered saline containing 0.05%
Tween (TBST) before overnight incubation at 4 C with
the appropriate primary antibody (diluted in 5% milk-
TBST). Membranes were then washed three times for
15 min with TBST and incubated with the appropriate
horseradish peroxidase (HRP) conjugated secondary
antibody (prepared in 5% milk-TBST) for 1 h at room
temperature. Following secondary antibody incubation,
blots were washed three times for 15 min with TBST
then visualized using a Pierce Enhanced
Chemiluminescence two detection kit (Fisher Scientiﬁc,
Loughborough, UK).
Western blot analysis was carried out using the
following primary antibodies:
From Millipore, Watford, UK:
GluN1 (mouse monoclonal, 05-432, 1:1000 dilution).
From R&D Systems, Abingdon, UK:
GluN2A (rabbit polyclonal, PPS012, 1:5,000);
GluN2B (rabbit polyclonal, PPS013, 1:5,000).
From Cell Signaling, New England Biolabs, Hitchin,
Herts, UK:
Post-synaptic density protein-95 (PSD-95) (rabbit
monoclonal, #3450, 1:10,000 dilution).
From Santa Cruz, Insight Biotechnology, Wembley, UK:
Doublecortin (goat polyclonal, sc-8066, 1:1000
dilution);
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clonal, sc-47990, 1:1000 dilution;
Unc5H1 (goat polyclonal, sc-67902, 1:1000
dilution);
Unc5H3 (goat polyclonal, sc-54442, 1:1000 or
1:500 dilution);
sonic hedgehog (Shh) (goat polyclonal, sc-1194,
1:1000 dilution);
Proliferating Cell Nuclear Antigen (PCNA) (mouse
monoclonal, sc-56, 1:1000 dilution);
Actin (goat polyclonal, sc-1615, 1:10,000 dilution).
The following secondary HRP-conjugated antibodies
were used at a 1:5000 dilution:goat anti-rabbit HRP
(12-348) (Millipore, Watford, UK); donkey anti-goat HRP
(sc-2020), goat anti-mouse (sc-2005), and donkey
anti-rabbit HRP (sc-2313) (Santa Cruz, Insight
Biotechnology, Wembley, UK).
Data analysis and statisticsElectrophysiology. Data from hippocampal slices are
presented as mean± 1 s.e.m. Baseline values for
potential size were obtained from a stable 10-min period
before any recording or manipulation, with the ﬁrst of
those potentials being deﬁned as 100%. Testing for
signiﬁcant diﬀerences between the plateau fEPSP size
following LTP induction was performed using a repeated
measures analysis of variance (ANOVA) for the last
5 min of recording, with individual time points compared
using the Bonferroni multiple comparison test.
Quantiﬁcation of LTP amplitude was achieved by
comparing the fEPSP size at time zero with the size
45 min after LTP stimulation, while comparison between
the LTP of control and knockout slices was performed
using ANOVA and the calculation of LTP magnitude
between the two groups was made by comparing the
fEPSPs at 45 min using a t test.
Immunoblotting. All western blots were quantiﬁed
using Image J software (http://rsb.info.nih.gov/ij/) and
comparisons were made statistically between groups of
pups born to mothers treated with kynurenine/
probenecid and groups born to mothers injected with
saline vehicle, or between the KMO(/) mice
compared with the Wild-Type controls. This protocol
allowed the use of a t-test to examine diﬀerences
between the two groups. To control for variations in the
total amount of protein loaded onto gels all samples
were examined after staining with Ponceau S stain. In
addition, actin levels were examined in each series of
blots and the ratio taken of the intensity of target protein
to the intensity of actin. A probability value of 0.05 was
adopted as the criterion for signiﬁcance.
RESULTS
Kynurenine with probenecidElectrophysiology and plasticity. The resting
excitability of CA1 pyramidal neurons was examined bymeasuring the size of the fEPSP in stratum radiatum at
increasing stimulation strength from the threshold
potential that elicited a detectable response (Fig. 1A).
The slopes of the potentials were compared up to the
stimulation strength which elicited the ﬁrst sign of a
population spike in the fEPSP. There were no signiﬁcant
diﬀerences between any of the data points in the
stimulus–response relationship between slices prepared
from control animals and those from animals born to
dams treated with kynurenine and probenecid (Fig. 1A).
When the analysis was performed for population spike
amplitude there were still no signiﬁcant diﬀerences
between the stimulus response curves for control and
kynurenine + probenecid-exposed animals (Fig. 1B).
Tests of paired-pulse facilitation (PPF) and inhibition
were performed using pairs of stimuli with inter-pulse
intervals from 100 ms (10 Hz) to 10 ms (100 Hz) with
digital subtraction of stimulation artifacts where
necessary, as described previously (Forrest et al.,
2013a,b) to examine PPF and paired-pulse inhibition
(PPI). The changes in the ratio of fEPSPs (Fig. 1C) or
population spike amplitudes (Fig. 1D) at diﬀerent inter-
pulse intervals were very similar between slices taken
from controls and animals exposed to kynurenine and
probenecid, with no signiﬁcant diﬀerences between the
groups.
The interaction between pairs of population spikes
varies with the frequency used to elicit the pulse pairs.
At increasing frequencies of presentation from the
normal 0.1 Hz up to 1 Hz, slices from control animals
show PPF which declined over a series of 5–10 stimulus
pairs with an overall decline of PPF measured on the
tenth stimulus pair and giving way to a small PPI at
1 Hz (Fig. 1E). In slices from animals exposed to
kynurenine and probenecid the decline in PPF with
repeated presentation was still observed but the switch
to PPI did not occur (Fig. 1E).
LTP was tested using theta stimulation (ﬁve bursts per
second, for 2 s, of four stimuli delivered at 100 Hz; Larson
et al., 1986). In control slices this level of stimulation
induced an increase of fEPSP amplitude which reached
a plateau after approximately 20 min and was stable until
the end of the recording period at 45 min (Fig. 1F, G). An
ANOVA was performed on the fEPSP slopes recorded
over the 10-min period before stimulation and between
40 and 45 min after theta stimulation, to ascertain whether
there were any signiﬁcant diﬀerences between the exper-
imental groups. The magnitude of the LTP was obtained
by comparing the amplitude at 45 min with the amplitude
immediately before theta stimulation, using a two-sample
t test.
In control animals there was an increase in fEPSP
amplitude of 80.2% (baseline 101.3 ± 6.1; LTP plateau
at 45 min 182.6 ± 8.1, n= 8, P< 0.0001) (Fig. 1F, G).
For slices prepared from animals exposed to kynurenine
and probenecid in utero, a comparison of the zero and
45-min time points showed that a lower level of LTP
was obtained compared with controls, with an LTP of
54.0% (baseline 96.3 ± 6.3; LTP plateau 147.9 ± 6.8,
n= 8, P< 0.0001). ANOVA conﬁrmed that the fEPSP
slopes between 40 and 45 min after inducing LTP were
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P< 0.0001), with all of the individual time points being
very signiﬁcantly diﬀerent (Fig. 1F, Bonferroni test).Since it is likely that the eﬀects of kynurenine loading
are due to its conversion to kynurenic acid, and
galantamine has been reported to reverse some eﬀects
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examined on the LTP. In order to assess the eﬀect of
galantamine only on NMDA receptor function, perfusion
with galantamine was preceded by superfusion with the
nicotinic receptor blockers methyl-lycaconitine (MLA) at
a concentration of 50 nM to block the predominant
a7-receptors as well as ab-subunit combinations
(Alkondon et al., 1992; Albuquerque et al., 2009) and
dihydro-b-erythroidine (DhbE, 10 lM). Atropine (0.1 lM)
was included to block muscarinic receptor activation
caused by the cholinesterase inhibitory activity of
galantamine. The addition of this cocktail to slices tended
to reduce fEPSP size but when compared after 10 min
this was not statistically signiﬁcant (baseline potentials
102.64 ± 5.8%, n= 5; potentials in cholinergic blocker
cocktail 97.4 ± 2.4%, n= 5, not signiﬁcant, t= 0.1).
Slices were then superfused with galantamine (10 lM)
beginning 10 min before the induction of LTP.
Galantamine had no eﬀect itself on the baseline fEPSPs
but at 45 min the fEPSP amplitude was increased by
107.5% of baseline (baseline, 98.3 ± 4.1; LTP 204.4
± 6.8; P< 0.0001, t test). ANOVA conﬁrmed that the
fEPSP slopes between 40 and 45 min after inducing
LTP were signiﬁcantly higher in the presence of
galantamine than in controls (F(9,70) = 3.45, P=0.0014),
with one of the individual time points being signiﬁcantly
diﬀerent (Fig. 1F, G; Bonferroni post hoc test).
In slices from animals exposed to kynurenine and
probenecid, galantamine increased the plateau LTP
even further, with ANOVA indicating a highly signiﬁcant
increase compared with controls (F(9,70) = 57.8,
P< 0.0001) and with all individual points signiﬁcantly
diﬀerent at P< 0.0001. At the 45-min time point, the
LTP reached 232.1% of the pre-stimulation level,
compared with the kynurenine and probenecid value of
154.0% (Fig. 1F, G; see above).Protein expression. In order to compare the possible
changes in protein expression induced by activation of
the kynurenine pathway rather than by its inhibition, the
proteins examined in this study included several which
were changed in our previous study of animals at 21 or
60 days of age after prenatal treatment with an inhibitor
of KMO (Forrest et al., 2013a,b). The range selected
included proteins involved in neuronal migration, axon
guidance, dendrite and spine formation as well as theFig. 1. Hippocampal function at P60 after prenatal exposure to kynurenine an
potentials (fEPSPs) and (B) population spikes (PS) as a function of stimulus
prenatally to kynurenine and probenecid. The symbols indicate mean ± s.e.
the pairs of data points. Paired-pulse data are shown for the ratio of fEPSPs r
the graph illustrate the digital subtraction performed for the recordings made a
(b) two responses at the 10-ms interval, and (c) the second response alone
directly superimposed traces (a) and (c) while (d) illustrates the superimposed
ratio of PS recorded in stratum pyramidale are shown in (D). The change in P
is shown in (E). The sample traces show individual records of paired PS at pr
records (G) illustrates long-term potentiation in the two groups of oﬀspring foll
50 nM, dihydro-b-erythroidine (DHbE, 10 lM) and atropine (100 nM) present f
zero. The inset records illustrate typical fEPSPs immediately before stimulatio
trace) in a slice from a control animal (J) or an animal exposed in utero to ky
enhancement of LTP by galantamine (triangles and insets Ia,b and Ha,b). S
10 ms. **P < 0.01; ***P < 0.001 using the Bonferroni test for multiple compari
3generation of functional synaptic contacts. The NMDA
receptor subunits GluN1, GluN2A and GluN2B were
examined since the NMDA receptors are thought to be
the primary site of action of kynurenic acid in the CNS,
although it can also block kainate or AMPA-sensitive pop-
ulations of glutamate receptor (Perkins and Stone, 1982).
The unco-ordinated locomotion-5 (unc5) family of proteins
comprises dependence receptors for the secreted ligand
netrin and is concerned with the balance between attrac-
tion and repulsion of growing neurites and cellular targets.
Lastly, three proteins involved in the cell cycle
(PCNA), and early neuronal maturation, diﬀerentiation
and migration (doublecortin, [DCX] and sonic hedgehog,
[Shh]) were examined. DCX is a microtubule-associated
protein expressed in cells early after mitosis (Couillard-
Despres et al., 2005) and which may be involved in disor-
ders of neocortical and hippocampal development
(Gleeson et al., 1999; Nacher et al., 2001; Corbo et al.,
2002). Shh protein is important in the formation of mor-
phogenetic gradients (Palma et al., 2005; Traiﬀort et al.,
2010) and the generation of functional synaptic contacts
(Angot et al., 2008; Hor and Tang, 2010) but it does per-
sist in the adult CNS (Traiﬀort et al., 1998; Charytoniuk
et al., 2002; Ahn and Joyner, 2005; Dellovade et al.,
2006).
In order to compare results directly with our previous
analysis of protein expression in animals treated with a
KMO inhibitor (Forrest et al., 2013a,b), we assayed
expression in the hippocampus. Although the expression
of several of these proteins was aﬀected by kynurenine
pathway inhibition at either P21 or P60, none showed
any signiﬁcant diﬀerence between control animals and
those treated with kynurenine and probenecid (Fig. 2).
KMO(/) miceElectrophysiology and plasticity. There were no
signiﬁcant diﬀerences between any of the data points in
the stimulus–response relationship between slices
prepared from Wild-Type mice and those deﬁcient in
KMO (Fig. 3A). When the analysis was performed for
population spike amplitude there were still no signiﬁcant
diﬀerences between the stimulus response curves for
Wild-Type and KMO(/) animals (Fig. 3B).
Tests of PPF and inhibition were performed as above
using pairs of stimuli with inter-pulse intervals fromd probenecid. The increase in size of (A) ﬁeld excitatory postsynaptic
current in the hippocampal CA1 region of adult (P60) rats exposed
mean (n = 12). There were no signiﬁcant diﬀerences between any of
ecorded in the stratum radiatum (C). The sample recordings alongside
t an interpulse interval of 10 ms, with (a) being a normal single fEPSP,
generated by the subtraction of (a) from (b). Record (d) shows the
traces adjusted to the same stimulus point. Paired-pulse data for the
S ratio at diﬀerent rates of paired-pulse presentation from 0.05 to 1 Hz
esentation rates of (a) 0.05 Hz and (b) 1 Hz. Panels (F) and enlarged
owing theta-burst stimulation at the arrow and with methyl-lycaconitine
rom the start of recordings. Galantamine (10 lM) was added from time
n (Ja, black trace) and the potentiated response 40 min later (Jb, gray
nurenine and probenecid (Ka,b). Panels (F) and (G) also illustrate the
ymbols indicate mean ± s.e.mean (n = 12). Calibrations 1 mV and
sons following ANOVA or t test comparison between individual points.
Fig. 2. Expression of proteins in the hippocampus of adult rats after prenatal exposure to kynurenine and probenecid. The panels summarize the
expression of several of the proteins examined in this study using Western blots. Data are shown for the optical density of blots relative to actin for
(A) GluN1, (B) GluN2A, (C) GluN2B, (D) unc5H1, (E) unc5H3, (F) doublecortin (DCX), (G) PCNA, (H) sonic hedgehog (Shh) and (I) actin. There
were no signiﬁcant diﬀerences (t-test) between columns (see Results); n = 6 for treated animals, n = 4 for controls).
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size and their ratios were also similar in slices taken from
KMO(/) and Wild-Type animals, with no signiﬁcant
diﬀerences observed (Fig. 3C) Slices from KMO(/)
animals showed a tendency to have consistently higher
levels of facilitation at the various inter-pulse intervals
but at none of the individual frequency points was there
a statistically signiﬁcant diﬀerence (Fig. 3D).
In slices from Wild-Type mice, theta stimulation
induced an increase of fEPSP amplitude which reached
a plateau after approximately 20 min and remained
stable until the end of the recording period (Fig. 3E, F).
The existence of signiﬁcant LTP was conﬁrmed by an
ANOVA comparison of the ﬁve fEPSPs before
stimulation with the ﬁve potentials elicited at the end of
recording (F(9,70) = 25.56, P< 0.0001). The magnitude
of the LTP plateau was quantiﬁed using a t test
comparison of the last of these ﬁve sets of stimuli which
revealed an increase of 57.7% in fEPSP amplitude from
98.7 ± 5.2 to 155.7 ± 6.1 (P< 0.0001, n= 8)For slices prepared from KMO(/) knockout animals
a similar LTP proﬁle was obtained, but smaller in size than
in Wild-Type slices (Fig. 3E, F). ANOVA conﬁrmed that
the KMO(/) fEPSPs were signiﬁcantly greater than
the corresponding pre-stimulation level (F(9,70) = 12.27,
P< 0.0001) with an increase of 31.2% between the
mean fEPSP slope at baseline (104.5± 3.3%) and that
at the end of recording (137.1 ± 5.0%) (P< 0.0001,
n= 8). A direct comparison of the ﬁnal ﬁve fEPSP
slopes from the two groups of mice indicated that the
LTP was signiﬁcantly smaller in the KMO(/) animals
compared with controls (F(9,70) = 3.83, P= 0.0006)
(Fig. 3E, F).
Protein expression. Since it was not possible to
compare directly protein expression in mice with our
previous results in rats, it was decided to limit protein
analysis to two speciﬁc regions of brain in the
experimental mice: the neocortex, which would be
primarily involved in some of the complex cognitive
Fig. 3. Hippocampal function in KMO(/) mice. The increase in size of (A) ﬁeld excitatory postsynaptic potentials (fEPSPs) and (B) population
spikes, as a function of stimulus current in the hippocampal CA1 region of control or KMO(/) mice. The symbols indicate mean ± s.e.mean
(n = 12). There were no signiﬁcant diﬀerences between any of the pairs of data points. (C) Paired-pulse data are shown for the ratio of fEPSPs
recorded in the stratum radiatum. The change in fEPSP ratio at diﬀerent rates of paired-pulse presentation is shown from 0.05 to 1 Hz. Symbols in
the graphs indicate mean ± s.e.mean (n = 12). The eﬀect of varying the rate of presentation of the paired-pulses is illustrated in (D). Panel (E)
illustrates long-term potentiation in the two groups of animals following theta-burst stimulation at the arrow. The ﬁnal 10 time points, within the box
indicated, are exploded in the inset panel (F). The sample potentials are of fEPSPs from (G) controls and (H) KMO(/) mice. The two records in
each sample are of a fEPSP immediately before theta stimulation (a) and the potentiated response 40 min later (b). The symbols indicate mean ± s.
e.mean (n = 8). Calibrations 1 mV and 10 ms. *P = 0.03 for the ﬁnal 5 min of recording (ANOVA). The symbols indicate mean ± s.e.mean (n = 6).
Calibrations 1 mV, 10 ms for the sample records.
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kynurenate levels, and the hippocampus which was the
region used for the examination of electrophysiological
properties and plasticity. The proteins examined
included the GluN2A subunit of the NMDA receptor,which was aﬀected by KMO inhibition in our previous
studies (Forrest et al., 2013a,b; Pisar et al., 2014). Several
of the proteins involved in neuronal guidance were
detected, including unco-ordinated 5H3 (unc5H3). In
addition, the expression of doublecortin and sonic
Fig. 4. Expression of neurodevelopmental proteins in the hippocampus and neocortex of adult KMO(/) mice. The panels illustrate the
expression of several of the proteins examined in this study by Western blots (n = 4/group) using the hippocampus (HIPPO) and neocortex (CX).
Data are shown for the optical density of blots relative to actin for (A) GluN2A (180 kDa), (B) PSD-95 (95 kDa), (C) DISC1 (70 kDa protein), (D)
DISC1 (100 kDa protein), (E) Unc5H3 (130 kDa), (F) Shh (45 kDa), (G) doublecortin (DCX; 45 kDa) and (H) actin (42 kDa).
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changed previously by KMO inhibition in vivo, either in
early postnatal life (P21) (Forrest et al., 2013a) or adult-
hood (P60) (Forrest et al., 2013b). Lastly, since a great
deal interest surrounds the possible role of kynurenines
in the initiation and development of schizophrenia, we
examined the protein DISC1. DISC1 has been linked to
the occurrence of schizophrenia and might be related to
activity in the kynurenine pathway if this is also relatedto the disorder. The absence of changes in any of these
proteins in the KMO(/) and WT groups (Fig. 4) indi-
cates an important diﬀerence between the results of phar-
macological KMO inhibition and its permanent removal.DISCUSSION
Glutamate receptors are intimately involved in brain
development and those sensitive to NMDA are
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formation (Udin and Grant, 1999; Dikranian et al.,
2001), neurite growth and spine formation (Ultanir et al.,
2007), many of these factors contributing to changes of
neuronal plasticity (Iwasato et al., 2000; Drian et al.,
2001; Fagiolini et al., 2003; du Bois and Huang, 2007).
Blocking NMDARs neonatally can lead to the loss or dis-
ruption of synapses with accompanying abnormalities of
brain structure and behavior (Dikranian et al., 2001).
One probable mechanism by which the activity of these
receptors can be regulated is through modulation of the
kynurenine pathway.
Tryptophan is oxidized to kynurenine by IDO in most
tissues (Stone and Darlington, 2002), although TDO per-
forms a similar function primarily, but not exclusively, in
the liver. IDO activity is induced by inﬂammatory media-
tors such as interferon-gamma (IFN-c) and by stress-
induced hormones such as corticosteroids. Since the
kynurenine pathway includes quinolinic acid as an agonist
at NMDARs (Stone and Perkins, 1981) and kynurenic
acid as an antagonist (Perkins and Stone, 1982), it there-
fore represents a potentially crucial link between immune
system activity or stress and the activity of glutamate
receptors (especially NMDARs) and hence brain
development.
Previous work using pharmacological inhibitors of the
kynurenine pathway or indirect activation by loading
animals with kynurenine has provided valuable
information on the biological consequences of modifying
pathway activity. The present study examined the
eﬀects of kynurenine loading in utero on the
development of the CNS in terms of hippocampal
electrophysiology and protein expression. The doses of
kynurenine and probenecid used in this study were
selected on the basis that they had been shown by
several diﬀerent laboratories to generate clear, robust
increases in kynurenine pathway metabolites (Miller
et al., 1992; Nozaki and Beal, 1992; Vecsei et al., 1992;
Shepard et al., 2003; Pocivavsek et al., 2012, 2014).
Kynurenine readily crosses the placental barrier so that,
as we have shown previously, increases in maternal
kynurenine and kynurenic acid loads are reﬂected in sim-
ilar changes in both compounds in their embryos (Forrest
et al., 2013a).
The value and eﬃcacy of using kynurenine loading for
exploring the actions of kynurenic acid in the CNS,
especially in relation to the etiology of schizophrenia
(Stone and Darlington, 2013) is reﬂected in the range of
functional and behavioral changes it produces. The
increase in kynurenic acid is associated with an inhibition
of CNS function, such as the suppression of allodynia and
chronic pain (Pineda-Farias et al., 2013), seizures
(Nemeth et al., 2004) and reduced abilities in learning
and other cognitive tasks (Alexander et al., 2013; Chess
et al., 2007, 2009; Pershing et al., 2015; Pocivavsek
et al., 2012, 2014; Shepard et al., 2003; Nilsson et al.,
2006). In several studies, increased kynurenic acid has
been shown to be protective against damage induced
by ischemia (Sas et al., 2008; Robotka et al., 2008) or tox-
ins such as 6-hydroxydopamine (Silva-Adaya et al.,
2011), amyloid-b (Carrillo-Mora et al., 2010) andquinolinic acid (Santamaria et al., 1996; Harris et al.,
1998). The concentrations that can be achieved by either
kynurenine administration or KMO inhibition are 10–100
times greater than those measured in normal mammalian
tissue but are likely to be relevant in pathological
conditions where CNS involvement occurs and where
behavioral aberrations are problematic, especially when
KMO activity is itself compromised. For example, changes
of this magnitude have been noted when infection develops
in the presence of KMO inhibition (Clark et al., 2005). A
similar interaction would be predicted in schizophrenic
patients who exhibit reduced kynurenine metabolism
(Sathyasaikumar et al., 2011) or who possess one of
the single nucleotide polymorphisms that suppress KMO
activity (Holtze et al., 2012; Wonodi et al., 2011, 2014)
and who also contract a signiﬁcant infection.
An important diﬀerence between KMO inhibition and
deletion is the absence of several changes in neuronal
and synaptic function. While changes were seen in
neuronal excitability after enzyme inhibition, no
diﬀerences were recorded in the knockout mice. These
data also imply that there are no changes in the
relationship between presynaptic transmitter release and
postsynaptic excitability (E–S coupling).
PPF was also comparable in normal and knockout
animals, despite a trend for a lower degree of facilitation
at all inter-pulse intervals. The failure to detect
signiﬁcant eﬀects raises doubts as to the physiological
signiﬁcance of this trend, although it may still be
suﬃcient to produce subtle, but critical changes in
overall network activity and plasticity. PPF is believed to
reﬂect the presynaptic persistence of intra-terminal
calcium accumulation and neurotransmitter release
(Zucker et al., 1991) and the results may suggest a reduc-
tion in this phenomenon in the absence of KMO. In sup-
port of the contention that a functional change has
resulted from KMO deletion, a tendency for a consistently
increased potential size was noted when the pairs of
pulses were delivered at increasing frequencies.
Changes were sought in the amplitude of LTP induced
by theta stimulation, which is generally considered to
mimic physiological activity more than a single tetanic
burst (Larson et al., 1986). The proﬁle of LTP was compa-
rable in Wild-Type and knockout slices with an early, large
short-term potentiation declining to a plateau over the
next 15–20 min. The observed reduction in amplitude of
the ﬁnal plateau LTP in knockout tissue may be attributa-
ble to increased levels of kynurenic acid measured in
these animals (Giorgini et al., 2013) and the ability of
kynurenic acid to block NMDA receptors could account
for this observation. Other antagonists at these receptors
are known to prevent LTP and the GluN2A subunit is
increased in rat hippocampus immediately after the induc-
tion of LTP (Baez et al., 2013), supporting the concept
that NMDA receptor activation is intimately involved in
the generation of the phenomenon and consistent with
the proposal that chronic blockade, as would be antici-
pated in KMO(/) mice, would partially suppress LTP.
The genetic deletion of KMO arguably provides a
better technical approach to the problem since it
removes uncertainties related to drug potency,
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introduces a new variable of acute or chronic enzyme
deﬁciency. A genetic model also provides a useful
comparison with potential abnormalities in human
subjects. The eﬀects of polymorphisms of KMO in the
blood of some patients with schizophrenia (Holtze et al.,
2012; Wonodi et al., 2014), reducing the expression or
activity of the enzyme, would be reproduced most faith-
fully by knockdown of KMO.
In both models, we have found changes in
hippocampal plasticity in adult animals. The reduced
LTP seen in slices from animals exposed in utero to
kynurenine and probenecid might simplistically be
explained on the basis that it reﬂects increased
concentrations of kynurenic acid in the brain slices,
capable of blocking glutamate receptors responsible for
the LTP. This conclusion is somewhat insecure, since it
would be expected that any excess of kynurenic acid
would be washed out of the slices during the
preparative and superfusion periods. It is more likely
that kynurenine pathway interference has lead to
compensatory, adaptive changes that develop or persist
into adulthood. A similar reduction of LTP was noted by
DeAngeli et al. (2015) 17 days following the administra-
tion of kynurenine to rats using an intermittent treatment
protocol which signiﬁcantly increased kynurenic acid
levels. The shorter post-treatment time involved, following
a longer period of administration would give less opportu-
nity for adaptation to occur and therefore supports the
present result. A similar treatment regime produced
behavioral deﬁcits in contextual fear conditioning and a
novel object recognition test (Akagbosu et al., 2012) and
increasing kynurenic acid levels during adolescence
induces abnormal social behaviors in adulthood which
are not reproduced by acute administration to adult ani-
mals (Trecartin and Bucci, 2011). It is likely, therefore,
that the results seen in adulthood reﬂect the marked
eﬀects which kynurenic acid can have on brain develop-
ment rather than indicating a maintained activity of resid-
ual kynurenate in the brain.
In the KMO(/) mice, however, there is a maintained
substantial increase in tissue kynurenate levels that could
contribute to the changes in plasticity.
Galantamine
The ability of kynurenic acid to antagonise NMDA and
other glutamate receptors has been studied in detail for
more than 30 years, although additional potential targets
have been proposed (see Stone et al., 2013). These
include antagonism of acetylcholine at nicotinic receptors
(Hilmas et al., 2001; Alkondon et al., 2003, 2011). How-
ever, several groups have failed to demonstrate any
antagonism by kynurenic acid at nicotinic sites (Arnaiz-
Cot et al., 2008; Mok et al., 2009; Dobelis et al., 2012),
except possibly at concentrations similar to, or higher
than, those at which it blocks NMDARs (Stone, 2007).
Galantamine (or galanthamine) has been employed
frequently as a test for the involvement of cholinergic
neurons in biological phenomena since it is an inhibitor
of acetylcholinesterase. In addition, it has allosteric
actions on nicotinic receptors, (Albuquerque et al.,2009). This property has formed the theoretical basis of
several studies in which galantamine has been used to
assess the role of a7NR in the actions of kynurenic acid
but galantamine is not entirely speciﬁc in its actions since
it has also been shown to facilitate the activation of NMDA
receptors (Moriguchi et al., 2004), to potentiate depolar-
ization produced by NMDA (Koola et al., 2014) and its
actions in vivo can be blocked by NMDA receptor antag-
onists (Schilstrom et al., 2007). This is a particular prob-
lem since NMDA receptor activation contributes to the
eﬀects of nicotinic receptor activation (Alkondon et al.,
2003). An agonist action on NMDA receptors would
account for the ability of galantamine to reverse the
behavioral eﬀects of NMDA receptor antagonists such
as dizocilpine in animal models of schizophrenia. For
example, galantamine reverses the suppression of pre-
pulse inhibition provoked by dizocilpine (MK-801) as a
model for schizophrenia (Shao et al., 2014; Su et al.,
2014). The present work shows that galantamine can
facilitate LTP, a phenomenon dependent on the activation
of NMDA receptors, in the presence of a nicotinic receptor
blocker, MLA. This is consistent with earlier reports that
galantamine can facilitate LTP (Moriguchi et al., 2009)
but conﬁrms that this can occur in the absence of nicotinic
receptor activation.
Protein expression
Given the previously recorded changes in GluN2A and
GluN2B subunit expression after prenatal KMO
inhibition (Forrest et al., 2013a,b), and the electrophysio-
logical changes after kynurenine and probenecid, it was
surprising to see no changes in protein expression here.
That may be because the functional changes in LTP
may either be the result of earlier alterations of NMDA
receptor expression that have now dissipated, or may
occur despite persisting but very limited changes in recep-
tor expression. The fact that many protein changes
detected at the time of weaning (P21; Forrest et al.,
2013a) have disappeared by P60 (Forrest et al., 2013b)
indicates that the brain may adapt or compensate for
those changes over time, leaving fewer molecular traces
of an insult while accumulating enough subtle shifts of
transduction pathways to leave functional changes in cell
communication or behavior.
In addition, kynurenine plus probenecid will push
metabolism along the pathway to kynurenic acid but the
changes produced will still be subject to normal
metabolic processes as the enzymes involved are not
only available to behave normally, but could be
up-regulated to compensate at least partly for the
increasing concentration of kynurenine and kynurenic
acid. The net result may be a smaller and shorter
duration of modulating kynurenine metabolite levels in
the embryo than is achieved by KMO inhibition.
It is also possible that the absence of altered protein
expression reﬂects a weaker eﬀect of kynurenine with
probenecid on metabolite levels in the embryo than
does inhibition of KMO. Enzyme inhibition, especially
maintained over several days of late gestation in our
previous studies, is likely to have produced a sustained
disruption of the kynurenine pathway at this key stage
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changes to the absolute levels of protein expression, but
also to changes in the time course of their generation
and, consequently, the ratios between their various
metabolites.
Alternatively, it is possible that the kinetics of
kynurenine penetration into the embryo brain are such
as to preclude substantial changes in kynurenic acid
levels comparable with those that have been reported in
the adult brain. This is probably unlikely since we have
shown comparable changes in embryo and maternal
brain concentrations of kynurenine and kynurenic acid at
the same time points after KMO inhibition (Forrest et al.,
2013a).
There are other diﬀerences between the
pharmacology of kynurenine and KMO inhibitors that
may also be relevant. For example, KMO inhibitors such
as Ro61-8048 are likely to act as ﬂavin-dependent
enzyme inhibitors in other unrelated pathways. Even
within the kynurenine pathway, KMO inhibition will lower
the ﬂux of kynurenine along the pathway to quinolinic
acid, nicotinic acid, nicotinamide (vitamin B3) and
NADPH and those changes might modify cellular
metabolism to a degree that potentiates the KMO
inhibition. Since these factors will either remain
unaﬀected by treatment with kynurenine and probenecid
or their concentrations will be increased rather than
decreased, they may contribute to the diﬀerent overall
eﬀects of KMO administration and kynurenine loading.
The selection of proteins whose expression was
studied in these animals was based on those shown
previously to change in response to prenatal treatment
with an inhibitor or KMO (Forrest et al., 2013a,b; Pisar
et al., 2014). The changes of NMDAR subunit expression,
which were apparent in the embryos as early as 5 h after
KMO inhibition (Forrest et al., 2013a), persisted into adult-
hood and were considered to contribute to alterations in
synaptic plasticity demonstrated in the adult hippocampus
(Forrest et al., 2013b; Khalil et al., 2014; Pisar et al.,
2014). The present ﬁnding that KMO deletion does not
aﬀect expression of the GluN2A subunits, however, sug-
gests that they may not be directly responsible for the
changes in plasticity. Rather, they may initiate or modu-
late developmental sequences earlier in development that
can lead to altered plasticity despite the progressive nor-
malization of the subunit expression. It has been sug-
gested, for example, that even a transient change in the
expression of such pivotal proteins could alter the abso-
lute or – at least as importantly – the relative temporal
expression of related proteins that would cause subse-
quent functional changes. Similar arguments may apply
to the other proteins examined.
Overall, KMO deletion does not result in as many
alterations of protein expression or hippocampal
function as did KMO inhibition. There are many possible
reasons for this. Both KMO inhibition and deletion result
in substantial (up to 100-fold) increases in kynurenic
acid concentrations (Giorgini et al., 2013; Forrest et al.,
2013a) which could be responsible for interfering with
NMDA receptor function in early brain development but
the diﬀerence between KMO inhibition and deletionsuggests that the changes observed do not simply reﬂect
increased levels of kynurenic acid. The most obvious dif-
ference between prenatal KMO inhibition and KMO dele-
tion is the time course of the insult. Following prenatal
inhibition of the enzyme, kynurenic acid levels would be
increased for only a few days, allowing ample time for a
raft of compensatory changes to occur in brain develop-
ment and maturation. In the deletion model the kynure-
nine pathway is disrupted continuously from the earliest
stages of development through to the various times of
postnatal testing. This may diﬀer from the inhibition model
in two extreme ways. It is possible that other kynurenine
pathway enzymes could compensate for the deletion
and the functional interference caused. Alternatively, it
is possible that the kynurenine pathway remains disrupted
but that most of its physiological functions are compen-
sated by adaptations in other, independent molecular
pathways or rearrangements of neural networks.
There remains a question of why the direct
administration of kynurenine produces fewer changes in
the brain than KMO inhibition, when both approaches
increase kynurenate levels to similar extents and with a
similar time course. The most obvious explanation is
that the KMO inhibitor (Ro61-8048) used by Forrest
et al. (2013a,b) may have additional actions on the kynur-
enine pathway, or on unrelated pathways involving a
ﬂavin-dependent oxygenase, that contribute to its eﬀects.
Those actions might then potentiate the eﬀects of KMO
inhibition, generating the range of brain changes
described which are not seen with kynurenine administra-
tion or KMO deletion.
There are other functional features of the kynurenine
pathway, such as the redox activity of several
metabolites (Giles et al., 2003; Darlington et al., 2010;
Colin-Gonzalez et al., 2014) or their regulation of immune
cell function (Nguyen et al., 2010; Stone et al., 2013;
Quak et al., 2014) which may make a signiﬁcant contribu-
tion to the observed changes in animals whose kynure-
nine pathway is modiﬁed. Some of the diﬀerences seen
between animals with KMO inhibition and KMO deletion
might then be attributable to those other factors, or the
balance between them.
CONCLUSIONS
Components of the kynurenine pathway, including
kynurenine, kynurenic acid and quinolinic acid, are
present during embryonic development (Beal et al.,
1992; Saito et al., 1993; Walker et al., 1999), and previous
results have shown the marked eﬀects on postnatal
development that can appear following prenatal inhibition
of that pathway (Forrest et al., 2013a,b; Khalil et al., 2014;
Pisar et al., 2014) and the functional and behavioral con-
sequences of interfering with it (Alexander et al., 2013;
Chess et al., 2007; Pocivavsek et al., 2012, 2014). Since
enzymes along the kynurenine pathway (mainly IDO and
KMO) are activated by pro-inﬂammatory cytokines
(Alberati-Giani et al., 1996), the present study supports
the concept that infection and/ or inﬂammation could inﬂu-
ence early brain development, perhaps contributing to the
established eﬀects of infection during pregnancy on
embryonic brain development (Brown, 2006, 2011;
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external factors could also aﬀect brain development by
interfering with the kynurenine pathway. Stress, for exam-
ple, induces corticosteroid secretion which induces and
activates TDO, while the diet includes compounds such
as the brassinins which inhibit the kynurenine pathway
(Banerjee et al., 2008).
Despite the diﬀerences between enzyme inhibition
and deletion models, the two approaches should reﬂect
diﬀerent clinical conditions. The previous enzyme
inhibition results should apply to situations in which
there is a temporary reduction in enzyme activity
caused either by reduced immune system induction or
the presence of an external inhibitory compound
originating in the environment or polypharmaceutical
treatment. Genetic deletion should reproduce the
situation in which there is a permanent loss of enzyme
protein or enzyme activity (Sathyasaikumar et al., 2011)
such as that occasioned by single nucleotide polymor-
phisms (Holtze et al., 2012; Wonodi et al., 2011, 2014).
Both models may, therefore, have clinical relevance.Acknowledgements—We are grateful to Epsom Medical
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